


# Thyroid gland


- *Glandula thyroidea* (15 - 20 g, frontal side of trachea under thyroid cartilage)
- Two lobes connected by thyroidal isthmus, *lobus pyramidalis*
- Strong vascularization
- Round follicles (acini) with one layer of **follicular cells (T3/T4)**
- Cavity filled with colloid
- Capillaries with fenestrations
- **Parafollicular (C-) cells (calcitonin)**
- From day 29 of gravidity (Tg), T4 – 11th week



**Figure 49-1** Structure of the thyroid gland. The thyroid gland is located anterior to the cricoid cartilage in the anterior neck. The gland comprises numerous follicles, which are filled with colloid and lined by follicular cells. These follicular cells are responsible for the trapping of iodine, which they secrete along with thyroglobulin—the major protein of the thyroid colloid—into the lumen of the follicle.

**Follicles are the basic functional units of thyroid gland**

# Thyroid gland




© 2008 Encyclopædia Britannica, Inc.



# Iodine and hormone secretion – general view

- NIS ( $\text{Na}^+/\text{I}^-$  symporter)
- PDS (pendrin)
- TPO (thyroidal peroxidase)
- TG homodimers and their iodation – MIT and DIT
- DUOX1 and 2 – together with TPO oxidation of iodide and transportation to TG structure
- TPO - connection DIT+DIT ( $\text{T}_4$ ) or DIT+MIT ( $\text{T}_3$ )
- Pinocytosis and phagolysosomes
- Deiodation of MIT and DIT – DEHAL1 (iodotyrosine dehalogenase)


- Other proteins (TSHR)
- Transcriptional factors (TTF-1, TTF-2, PAX8, HNF-3)



# Dietary iodine

Recommended Daily Intake	
Adults	150 µg
During pregnancy	200 µg
Children	90-120 µg
Typical Iodine Daily Intakes	
North America (1992)	75-300 µg
Chile (1981)	<50-150 µg
Belgium (1993)	50-60 µg
Germany (1993)	20-70 µg
Switzerland (1993)	130-160 µg

- Bioavailability of organic and inorganic I
- ECF + Ery, saliva, gastric juice
- breast milk
- I<sup>-</sup> filtered with passive reabsorption 60 – 70 %
- loss through stool (10 – 20 µg/day)
- Highest daily intake in Japan (several mg)
- In many countries on decrease – eating habits



## Clinical relevance

- Endemic goiter
- Endemic cretinism

# Iodine fate in follicular cells

## NIS

- Concentration of I in follicular cells
- Transport of other ions ( $\text{TcO}_4^-$ ,  $\text{ClO}_4^-$ ,  $\text{SCN}^-$ ) – clinical significance
- Salivary glands, mammary gland, choroid plexus, gastric mucosa, cytotrophoblast, syncytiotrophoblast
- Loss of ability to concentrate I in thyroid gland tumors
- TSH
  - (+) transcription
  - (+) prolonged stay in PM

## Pendrin

- also kidneys ( $\text{Cl}^-/\text{HCO}_3^-$  exchanger) and inner ear

## Chloride channel 5 (ClCn5)

- ?

## DEHAL1

- MIT and DIT, iodine recycling

## IYD

- iodotyrosine deiodinase
- MIT (+++), DIT (+)


## Clinical relevance

- Mutation
- Thiourea derivatives – methimazole, carbimazole, propylthiouracil (TPO)

# Oxidation, organification of iodine and MIT/DIT synthesis

- Organification = incorporation I in MIT and DIT
- TPO in cooperation with DUOX1 and DUOX2 – peroxide generation
- DUOX1/2 – NADPH, Ca<sup>2+</sup>-dependent oxidases
- generation of I<sub>2</sub> and I<sup>+</sup>
- DUOXA2 – maturation and DUOX2 incorporation
- TSH stimulation

- T3 and T4 –TPO catalysis
- Tg – tyreoglobulin, 660 kDA homodimer
- Tg – 134 tyrosines / 25 – 30 iodinated / only 3, resp. 4, participate in T4 and T3
- 3 – 4 molecules of T4 in Tg (physiological conditions)
- Only 1 T3 in Tg



# T3 and T4 secretion

- High supply vs low daily turnover (about 1 %)
- Supply ca 5000  $\mu\text{g}$  T4 – euthyroid state for ca 50 days

- Macropinocytosis and **micropinocytosis** (apical membrane)
- Endocytosis
- Lysosomes fusion
- Selective proteolysis (cathepsin D and D-like thiol proteases, active at low pH)
- Release of hormones from Tg in lysosomes
- Potential cytosolic transporter? (MCT8)
- T4 available to deiodases D1 and D2 – modulation of systemic conversion?
- Inhibition of T4 secretion by iodide

## TSH and T3, T4 secretion

- TSHR
  - TSH binding
  - TRAb (TSHR-stimulating antibody )
  - TBAb (thyroid-blocking antibodies )
  - LH (+)
  - hCG (+)
- G prot. – 11 subtypes of  $\alpha$  subunit
- $G_s$
- $G_{q/11}$
- PLC +  $\text{Ca}^{2+}$ 
  - iodide efflux, peroxide generation, iodation of Tg
- PKA
  - iodide uptake
  - Tg transcription
  - transcription and generation of TPO and NIS

# T3 and T4 transport

## TBG

- Glycoprotein
- One binding site for iodothyronine
- Half-life ca 5 days
- Clinical significance – sepsis, cardiopulmonary surgery – cleavage by polymorphonuclear proteases – part of defensive reaction?

## Transthyretin

- Binds one T4 molecule, low affinity
- Half-life ca 2 days
- CSF – relevance ?
- Clinical significance – amyloid polyneuropathy

## Albumin

- Low affinity
- Little relevance for T3/T4 transport (max. 10 %)

Other – lipoproteins (3 – 6 %)

Parameter	Thyroxine-Binding Globulin	Transthyretin	Albumin
Molecular weight of holoprotein (kDa)	54,000	54,000 (4 subunits)	66,000
Plasma concentrations ( $\mu\text{mol/L}$ )	0.27	4.6	640
T <sub>4</sub> binding capacity as $\mu\text{g T}_4/\text{dL}$	21	350	50,000
Association constants of the major binding site (L/mol)			
T <sub>4</sub>	$1 \times 10^{10}$	$7 \times 10^7$	$7 \times 10^5$
T <sub>3</sub>	$5 \times 10^8$	$1.4 \times 10^7$	$1 \times 10^5$
Fraction of sites occupied by T <sub>4</sub> in euthyroid plasma	0.31	0.02	<0.001
Distribution volume (L)	7	5.7	7.8
Turnover rate (% day)	13	59	5
Distribution of iodothyronines (% protein)			
T <sub>4</sub>	68	11	20
T <sub>3</sub>	80	9	11

T<sub>3</sub>, triiodothyronine; T<sub>4</sub>, thyroxine.

**Low solubility of iodothyronines determines their reversible binding and transport by plasmatic proteins.**



# Free T3/T4



$$\frac{T_4 \cdot TBG}{(T_4)(TBG)} = k_a$$

$$\frac{T_4}{T_4 \cdot TBG} = \frac{1}{(TBG)k_a}$$

Importance of glomerular filtration

Glucuronidation of T4 = elimination of T4-G through bile

Parameter	T <sub>3</sub>	T <sub>4</sub>
Production rate (nmol/day)	50	110
Fraction from thyroid	0.2	1.0
Relative metabolic potency	1.0	0.3
Serum concentration		
Total (nmol/L)	1.8	100
Free (pmol/L)	5	20
Fraction of total hormone in free form ( $\times 10^{-2}$ )	0.3	0.02
Distribution volume (L)	40	10
Fraction intracellular	0.64	0.15
Half-life (days)	0.75	6.7


To convert T<sub>4</sub> from nmol/L to  $\mu$ g/dL (total) or pmol/L to ng/dL (free), divide by 12.87. To convert T<sub>3</sub> from nmol/L to ng/dL (total) or pmol/L to pg/dL (free), multiply by 65.1.

**TBG concentration and saturation is the main free-T4 determinant.**

# T4/T3 transport across PM and their cell fate

Transport systems:

- MCT8 (monocarboxylate transporter 8)
  - MCT10 (monocarboxylate transporter 10)
- } Expression in various tissues T3, T4, rT3
- OATP1C1 (organic anion transporting polypeptide 1C1) (HEB)
- } CNS (astrocytes) T4



Two-way transport of T3

Role of deiodinase type II


Extrahypophyseal tissues

- 90 % T3 in cytosol
- 10 % T3 in nucleus

Hypophysis

- 50 % T3 in cytosol
- 50 % T3 in nucleus

# Deiodination and (seleno-)deiodinases




- all deiodinases require thiol presence as cofactor (glutathione (GSH), thioredoxin (TRX), glutaredoxin (GRX))
- D1 - main source of plasmatic T<sub>3</sub>
- D3 - most important „deactivating“ enzyme over-expressed in tumor tissue

Parameter	Type 1 (Outer and Inner Ring)	Type 2 (Outer Ring)	Type 3 (Inner Ring)
Physiologic role	rT <sub>3</sub> and T <sub>3</sub> S degradation, the source of plasma T <sub>3</sub> in thyrotoxic patients	Provide intracellular T <sub>3</sub> in specific tissues, a source of plasma T <sub>3</sub>	Inactivate T <sub>3</sub> and T <sub>4</sub>
Tissue location	Liver, kidney, thyroid, pituitary (?) (not CNS)	CNS, pituitary, BAT, placenta thyroid, skeletal muscle, heart	Placenta, CNS, hemangiomas, fetal or adult liver, skeletal muscle
Subcellular location	Plasma membrane	Endoplasmic reticulum	Plasma membrane
Preferred substrates (position deiodinated)	rT <sub>3</sub> (5'), T <sub>3</sub> S (5)	T <sub>4</sub> , rT <sub>3</sub> (5')	T <sub>3</sub> , T <sub>4</sub> (5)
K <sub>m</sub>	rT <sub>3</sub> , 10 <sup>-7</sup> ; T <sub>4</sub> , 10 <sup>-6</sup>	10 <sup>-9</sup>	10 <sup>-9</sup>
Susceptibility to PTU	High	Absent	Absent
Response to increased T <sub>4</sub>	↑	↓	↑

BAT, brown adipose tissue; CNS, central nervous system; K<sub>m</sub>, Michaelis-Menten constant; PTU, 6-n-propylthiouracil; rT<sub>3</sub>, reverse triiodothyronine; T<sub>3</sub>, triiodothyronine; T<sub>3</sub>S, T<sub>3</sub>SO<sub>4</sub>; T<sub>4</sub>, thyroxine.

# Sources of intracellular T3 and T4



D2 as a source of supplementary nucleic T3

T3 supply critical for tissues:

- cortex
- BAT
- PIT

Physiological relevance:

- Normal development
- Thyroid gland function regulation
- Cold

Clinical relevance

- Amiodarone (D1/D2 (-))
- Propylthiouracil (D1 (-))
- Glucocorticoids (D3 (+))

Preferential plasmatic T3 utilization

# T3/T4 – mechanism of action

-TR

-TR $\alpha_1$

-TR $\beta_1$

-TR $\beta_2$

-TR $\beta_3$

CNS, BAT, skeletal muscle, GIT,  
lungs, heart

All tissues, mainly kidneys, liver

Hypothalamus and hypophysis

Very low expression, mainly liver,  
kidneys, lungs




Feedback regulation of T3/T4 bradycardia, hypothermia

-Heterodimer with RXR

-TRs binding

- T3 with 15-fold affinity compared to T4



# Physiological effects of thyroid hormones



- Non-nuclear receptors
- Interactions with adaptor proteins



- cAMP
  - MAPK
  - Ca<sup>2+</sup>-ATPase (+)
  - Na<sup>+</sup>/H<sup>+</sup> antiporter (+)
- 
- Cell response



- Regulation of transcriptional activity



- Normal growth and development
- Regulation of metabolism

# Organ-specific effects of thyroid hormones

## Bones

- Bone growth and development
- regulation of activity of osteoblasts/clasts, chondrocytes
- hyperthyroidism – risk of osteoporosis

## Cardiovascular system

- Inotropic and chronotropic effect
- (+) cardiac output and IVF
- (-) vascular resistance
- changes in transcriptional activity:
  - Ca<sup>2+</sup>-ATPase
  - Phospholamban
  - Myosin
  - β-AR
  - AC
  - Na<sup>+</sup>/Ca<sup>2+</sup> exchanger
  - Na<sup>+</sup>/K<sup>+</sup>-ATPase
  - Voltage-gated ion channels

## GIT

- (+) monosaccharides resorption
- (+) motility

## Adipose tissue

- (+) differentiation of adipose tissue, adipocytes proliferation
  - (+) lipogenic enzymes
  - (+) cell accumulation of lipids
  - (+) uncoupling proteins, uncoupling of oxidative phosphorylation
  - Hyperthyroidism (+) lipolysis
    - (+) β-AR
    - (-) phosphodiesterase activity
    - (+) cAMP
  - Hypothyroidism (-) lipolysis
- } (+) activity HSL

## Liver

- regulation of triglyceride, lipoprotein and cholesterol metabolism
- (+) fatty acids metabolism
- (+) gluconeogenesis
- (+) mitochondrial respiration

## CNS

- expression of genes related myelination, cell differentiation, migration and signaling
- Axonal growth and further development


# TG regulation – hypothalamo-hypophyseal axis

## TRH

- hypothalamus, CNS, C cells of TG,  $\beta$  cells of pancreas, myocardium, reproductive organs (prostate, testes), spinal cord
- Necessity of T3 and T4, relevance of D2
- TRH-DE (TRH-degrading ectoenzyme)

## TSH

- Half-life ca 30 min
- Pulsatile secretion, connected to circadian rhythms
- Magnitude changes – starvation, disease, surgery
- Leptin, ADH, GLP-1, glucocorticoids,  $\alpha$ -adrenergic agonists, prostaglandins, TRH (+)
- T3/T4, gastrin, opioids, glucocorticoids (high doses), serotonin, CCK, IL-1 $\beta$  a 6, TNF- $\alpha$ , somatostatin (-)



Synthesis and secretion of thyroid hormones is regulated by feedback mechanism.



# Iodide deficit and excess

## Deficit

- Rapid T4 decrease, TSH increase
- No change in T3
- Increased synthesis of NIS, TPO, Tg, organification of iodide and Tg turnover
- Increase D2 in CNS, hypothalamus and hypophysis
- Stimulation of follicular cells (TSH)
- Long-term deficit – decreased D3
- Decrease supplementation under 75  $\mu\text{g}/\text{day}$  (China, India, Indonesia, Africa)
- hypothyroidism

## Excess


- At first increase, then decrease of iodide organification (Wolff–Chaikoff effect)
- Long-term high iodide supplementation = hypothyroidism and goitre
- decreased NIS generation
- Immediate inhibition of thyroid hormones secretion



# Functions of thyroid gland in fetus and newborn

Physiologic Change	Thyroid-Related Consequences
↑ Serum thyroxine-binding globulin	↑ Total T <sub>4</sub> and T <sub>3</sub> ; ↑ T <sub>4</sub> production
↑ Plasma volume	↑ T <sub>4</sub> and T <sub>3</sub> pool size; ↑ T <sub>4</sub> production; ↑ cardiac output
D3 expression in placenta and (?) uterus	↑ T <sub>4</sub> production
First trimester ↑ in hCG	↑ Free T <sub>4</sub> ; ↓ basal thyrotropin; ↑ T <sub>4</sub> production
↑ Renal I <sup>-</sup> clearance	↑ Iodine requirements
↑ T <sub>4</sub> production; fetal T <sub>4</sub> synthesis during second and third trimesters	
↑ Oxygen consumption by fetoplacental unit, gravid uterus, and mother	↑ Basal metabolic rate; ↑ cardiac output

D3, type 3 iodothyronine deiodinase; I<sup>-</sup>, plasma iodide; hCG, human chorionic gonadotropin; T<sub>3</sub>, triiodothyronine; T<sub>4</sub>, thyroxine.



# Thyroid gland and development stages

## Fetal thyroid gland - qualitative and quantitative differences

- 10-fold higher T4 production
- D1 (-), D3 (+; liver, skin, tracheobronchial system, urothelial system, GIT epithelium) – T3(-), rT3 (+)
- D2 – generation of T3 in tissues
- Start at the beginning of the 3rd trimester
- TSH during whole development higher than in mother
- Almost no interaction with mother (exception placental transport of T4), high expression of D3 in uterus and placenta

## Thyroid gland in newborns - qualitative and quantitative differences

- Increased TBG level
- Lower T4 levels compared to mother
- Low T3 level in serum, increased levels of rT<sub>3</sub> and T<sub>3</sub>SO<sub>4</sub>
- Rapid increase TSH 2 – 4 hours after birth, decrease in 48 hours
- Rapid increase T<sub>4</sub>, T<sub>3</sub>, Tg – 24 hours (+D1 a D2, adrenergic stimulation of D2 in BAT)

## Thyroid gland and aging

- Normal T4 level, decreased T3 level
- TSH according to iodide supplementation
- Benefit of decreased thyroid hormones - longevity

# Thyroid gland functions during disease and starvation

## Starvation

- Decreased plasmatic T3, increased rT3, T4 no change
  - Upregulation of D3
  - Decreased oxygen consumption
  - Slower heart rate
  - More positive nitrogen balance
- = **mechanisms to save energy and proteins**

- Chronic malnutrition – decreased plasmatic T3

## Disease

- Changes in T4 to T3 D2) conversion – TSH binding
- IL-6
- Increased intra-/extracellular ROS = changes in deiodinase activity – decreased T4 to T3 conversion  
BUT! no change in D3
- potential therapy – infusion of TSH + GHRP2
- Bipolar disorder – (+) TSH, (-) T4
- Severe depression – (-) TSH, (+) T4

Severity of Illness	Free T <sub>3</sub>	Free T <sub>4</sub>	Reverse T <sub>3</sub>	TSH	Probable Cause
Mild	↓	N	↑	N	↓ D2, D1
Moderate	↓↓	N, ↑↓	↑↑	N, ↓	↓↓ D2, D1, ? ↑ D3
Severe	↓↓↓	↓	↑	↓↓	↓↓ D2, D1, ↑ D3
Recovery	↓	↓	↑	↑	?

D1 through D3, iodothyronine deiodinases; N, no change; T<sub>3</sub>, triiodothyronine; T<sub>4</sub>, thyroxine; TSH, thyroid-stimulating hormone (thyrotropin).

# Hormones and thyroid gland

## Glucocorticoids

- Decreased pulsatile secretion of TSH and TRH secretion
- Increased activity (expression) of D3

## Sex steroids

- Estrogens
  - increased TBG
  - TSH (+ 15 – 20 %)
- Androgen
  - decreased TBG

## GH

- (+) T3, (-) T4
- Deiodinase

## Glucocorticoids

### *Excess*

- Decrease TSH, TBG, TTR (high-dose)
- Decrease serum  $T_3/T_4$  and increase  $rT_3/T_4$  ratios
- Increase  $rT_3$  production (?  $\uparrow$  D3)
- Decrease  $T_4$  and  $T_3$  secretion in Graves disease

### *Deficiency*

Increase TSH

## Estrogen

- Increase TBG sialylation and half-life in serum
- Increase TSH in postmenopausal women
- Increase  $T_4$  requirement in hypothyroid patients

## Androgen

- Decrease TBG
- Decrease  $T_4$  turnover in women and reduce  $T_4$  requirements in hypothyroid patients

## Growth Hormone

Decrease D3 activity

D3, type 3 deiodinase;  $rT_3$ , reverse  $T_3$ ;  $T_3$ , triiodothyronine;  $T_4$ , thyroxine; TBG, thyroxine-binding globulin; TSH, thyrotropin; TTR, transthyretin.

# Hypothyroidism

Disruptions of HYP-ADH-TG axis including mutations

Goitrogens and treatment

## Primary versus secondary

- Cold sensitivity
- Dry cold skin
- Slower movements
- Slow quiet speech
- Bradycardia
- Water retention
  
- **Psychomotoric retardation** (children)
- **Myxedema** (accumulation of protein complexes, polysaccharides, hyaluronic acid and chondroitin sulfuric acid in skin)
- Hypothyroidism since birth = **cretinism**



# Hypothyroidism

Graves disease, diffusion toxic goiter, toxic nodular goiter, inappropriate pharmacotherapy, excessive iodide intake, thyroiditis, follicular carcinoma, tumors producing TSH

- increased BMR
- Changes in catecholamines reactivity
- **Exophthalmos** - infiltration of lymphocytes and periocular fibroblasts into extraocular muscles and tissue
- unrest
- **Tachycardia**
- Hyperventilation



# Hypo- versus hyperthyroidismus

Parameter	Hypothyroidism	Hyperthyroidism
BMR	(-)	(+)
Carbohydrate metabolism	Gluconeogenesis (-) Glycogenolysis (-) Glycemia (N)	Gluconeogenesis (+) Glycogenolysis (+) Glycemia (N)
Protein metabolism	Proteosynthesis (-) Proteolysis (-)	Proteosynthesis (+) Proteolysis (+) Muscle mass (-)
Lipid metabolism	Lipogenesis (-) Lipolysis (-) Serum cholesterol (+)	Lipogenesis (+) Lipolysis (+) Serum cholesterol (-)
Thermogenesis	(-)	(+)
Autonomic nervous system	Plasmatic catecholamines (N)	Increased reactivity – $\beta$ -AR (+) Plasmatic catecholamines (-)



# Examination of hypothalamus – adenohypophysis – thyroid gland axis

**TSH** – immumometric methods

**Overall T3 and T4** – immunochemical methods (immunoassays)

Free T3 and T4

**rT3**

**Antibody levels** - (anti-Tg, anti-TPO, TSIs – thyroid-stimulating immunoglobulins)

**Thyroid nodules** – ultrasound, biopsy, scan – I-123, Tc-99